August 12, 2026 — RNews

#tyrosine-kinase-inhibitors — Wednesday, August 12, 2026 (1 items)

hot top new

← prev day next day →

20

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. (linkinghub.elsevier.com)

Motzer RJ … Schmidinger M The Lancet 2026-08-12

#renal cell carcinoma #clinical trial #immunotherapy #oncology #tyrosine-kinase-inhibitors